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OBJECTIVES The objective of our study was to assess the hemodynamic effects of immunoadsorption (IA)
and subsequent immunoglobulin G (IgG) substitution in comparison with the effects of
conventional medical treatment in patients with dilated cardiomyopathy (DCM).
BACKGROUND Various circulating cardiac autoantibodies have been detected among patients suffering from
DCM. These antibodies are extractable by IA.
METHODS Patients with DCM (n 5 18, New York Heart Association III–IV, left ventricular ejection
fraction ,30%) and who were on stable medication participated in the study. Hemodynamic
measurements were performed using a Swan-Ganz thermodilution catheter. The patients
were randomly assigned either to the treatment group with IA and subsequent IgG
substitution (IA/IgG group, n 5 9) or to the control group without IA/IgG (n 5 9). In the
IA/IgG group, the patients were initially treated in one IA session daily on three consecutive
days. After the final IA session, 0.5 g/kg of polyclonal IgG was substituted. At one-month
intervals, IA was then repeated for three further courses with one IA session daily on two
consecutive days, until the third month.
RESULTS After the first IA course and IgG substitution, cardiac index (CI) increased from 2.1 (60.1)
to 2.8 (60.1) L/min/m2 (p , 0.01) and stroke volume index (SVI) increased from 27.8
(62.3) to 36.2 (62.5) ml/m2 (p , 0.01). Systemic vascular resistance (SVR) decreased from
1,428 (674) to 997 (655) dynezszcm25 (p , 0.01). The improvement in CI, SVI and SVR
persisted after three months. In contrast, hemodynamics did not change throughout the three
months in the control group.
CONCLUSIONS Immunoadsorption and subsequent IgG substitution improves cardiovascular function in
DCM. (J Am Coll Cardiol 2000;35:1590–8) © 2000 by the American College of
Cardiology
Dilated cardiomyopathy (DCM) is a myocardial disease
characterized by progressive depression of myocardial con-
tractile function and by ventricular dilatation (1).
Disturbances in both humoral and cellular immunity have
been described in patients with myocarditis and DCM
(2,3). A number of antibodies against cardiac cell proteins
have been identified in DCM; these include antibodies
against mitochondrial proteins (4), contractile proteins (5)
and cardiac beta-receptors (6,7). For some cardiac antibod-
ies, it has been possible to demonstrate direct cardiodepres-
sant effects (4,8). The functional role of cardiac autoanti-
bodies in DCM is still unclear. They may reflect an
inflammatory response to myocyte necrosis, thereby repre-
senting an epiphenomenon. On the other hand, cardiac
autoantibodies may also play an active role in the pathogen-
esis of DCM by initiating the disease process or by
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contributing to the progression of myocardial contractile
malfunction. If cardiac autoantibodies do, in fact, contribute
to cardiac malfunction in DCM, their removal would be
expected to improve the hemodynamics of patients with
DCM. Cardiac antibodies are extractable by immunoad-
sorption (IA) (9).
We recently performed the first uncontrolled pilot study
conducted to ascertain the short-term hemodynamic effects
of IA in patients with DCM (9). Immunoadsorption
induced significant decrease in immunoglobulin (Ig) G
(IgG) serum levels, as well as consistent reduction of
beta-receptor antibodies. The cardiac index (CI) rose and
systemic vascular resistance (SVR) simultaneously fell.
These data suggest that removal of antibodies improves
hemodynamics in DCM.
Intravenous Ig treatment also influences the immune
system by means of various mechanisms (10). The autoan-
tibodies are neutralized by the anti-idiotypic properties of
intravenous IgG, thus preventing binding of the autoanti-
bodies to its antigen. Furthermore, binding of anti-idiotypic
Igs to B-cell Fc receptors decreases the production of
autoantibodies in B cells. Finally, intravenous IgG modu-
lates cellular immunity and cytokine metabolism (10). Im-
munoglobulin treatment as well as IA have been successfully
used for treatment of various autoimmune diseases such as
immune thrombocytopenic purpura, myasthenia gravis and
polyneuropathy in the form of Guillain-Barre´ syndrome
(11–16). Interestingly, recent data from an uncontrolled
study published by McNamara et al. (17) indicate that
intravenous Ig therapy may also be useful in treatment of
patients with new-onset dilated cardiomyopathy. In patients
with myocarditis and acute cardiomyopathy, application of
intravenous IgG was associated with significant improve-
ment in left ventricular performance as a long-term effect.
The combination of IA and intravenous IgG administration
may, therefore, represent a promising therapeutic principle
in treatment of DCM. This study investigated the acute and
prolonged effects of IA and subsequent IgG substitution in
patients with DCM, in comparison with a control group
without IA and IgG substitution.
METHODS
Study patients. Included in this study were male patients
suffering from DCM (n 5 18) and left ventricular dysfunc-
tion (left ventricular ejection fraction [LVEF] ,30%, as
assessed by cineangiography or two-dimensional echocardi-
ography), as well as from severe chronic heart failure (New
York Heart Association [NYHA] III–IV) refractory to
medical therapy. The hemodynamic inclusion criteria as-
sessed by a Swan-Ganz thermodilution catheter were CI
#2.5 liters/min/m2 or pulmonary capillary wedge pressure
(PCWP) $16 mm Hg. Coronary heart disease—in partic-
ular, relevant stenoses (.40% of vessel diameter) of the
coronary arteries—were excluded by coronary angiography,
and the possibility of acute myocarditis was eliminated by
histological examination of myocardial biopsies in all cases
studied. Serum levels of cholesterol and low-density li-
poprotein cholesterol did not differ significantly at baseline
between the treatment group and the control group. Three
patients from the control group and one from the treatment
group had elevated levels of cholesterol (.200 mg/dl,
,280 mg/dl). Three patients (one from the control group
and two from the treatment group) had noninsulin-
dependent diabetes mellitus and two (one from the control
group and one from the treatment group) had insulin-
dependent diabetes mellitus. All patients had received stable
oral medication for more than three months before this
study. All patients were treated with angiotensin converting
enzyme (ACE) inhibitors, digitalis and diuretics. Thirteen
patients received nitrates. Four patients were treated with a
beta-adrenergic blocking agent. In these four cases the doses
of the beta-blockers had been stable at least six months
before this study. At baseline, medication and dosage for the
treatment group did not differ significantly from that for the
control group. Patients were excluded if they had a history
of arterial hypertension, myocardial infarction, heart failure
due to other known origins (e.g., primary valvular disease)
or if they had suffered from active infectious diseases, cancer
or chronic alcoholism.
Written consent was obtained from each patient, and the
protocol was approved by the Charite´ Hospital Ethics
Committee.
Hemodynamics. The patients were transferred to the in-
tensive care unit for hemodynamic monitoring. We con-
ducted right-heart catheterization with a Swan-Ganz ther-
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
BPmean 5 mean arterial blood pressure
CI 5 cardiac index
DCM 5 dilated cardiomyopathy
HR 5 heart rate
IA 5 immunoadsorption
Ig 5 immunoglobulin
IgG 5 immunoglobulin G
IL 5 interleukin
LVEDD 5 left ventricular end-diastolic
diameter
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
PAPmean 5 mean pulmonary arterial pressure
PCWP 5 pulmonary capillary wedge
pressure
PVR 5 pulmonary vascular resistance
RAP 5 right atrial pressure
sIL-2R 5 soluble IL-2 receptor
sTNF-R1 and -R2 5 soluble tumor necrosis factor
receptor I and II
SVI 5 stroke volume index
SVR 5 systemic vascular resistance
TNFalpha 5 tumor necrosis factor alpha
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modilution catheter to evaluate patient hemodynamics.
Measurements were carried out four times a day. The
interval between two hemodynamic measurements was at
least 3 h. The hemodynamic values given in tables and
figures represent the mean values from hemodynamic mea-
surements performed four times a day. We employed
two-dimensional echocardiography. The readings were re-
corded, and assessment of LVEF took place off-line by a
reader blinded to the treatment group. Left ventricular
ejection fraction was measured according to the Simpson
rule.
Immunoadsorption. After completion of baseline mea-
surements, Ig extraction from the plasma was performed
using Ig Therasorb (Baxter, Munich, Germany), an immu-
noadsorber for immunoglobulin. The extracorporeal IA
system (Microsorb Dialyse Technik, Ettlingen, Germany)
consisted of conventional plasmapheresis and immuno-
apheresis systems. We used a Hemaplex-BT 900/B plasma
filter (Dideco, Mirandola, Italy) for conventional plasma-
pheresis. The plasma was separated at a maximum flow rate
of 30 ml/min, passed through the IA column, and then
reinfused. The IA system employed consisted of two parallel
columns. Plasma passes through one of the columns (plasma
filling volume 5 100 ml) while the other is being regener-
ated. During IA, anticoagulation was performed with intra-
venous infusion of heparin.
Study protocol. All patients who had been on long-term
oral medication on a stable basis for more than three months
were transferred to the intensive care unit. Hemodynamic
baseline measurements were carried out four times on day 1.
On the following day (day 2), the patients were randomly
assigned either to treatment with IA and subsequent IgG
substitution (IA/IgG group, n 5 9) or to the control group
without IA or IgG treatment (n 5 9) on the basis of
closed-label randomization. On days 2 through 5, hemody-
namic measurements were continued four times a day in the
IA/IgG group as well as in the control group.
In the IA/IgG group, IA was performed in four courses,
at one-month intervals, until month 3, as indicated in
Figure 1. During the first course (course I), all patients of
the IA/IgG group underwent one IA session daily on three
consecutive days. Each session was continued until 5 liter of
plasma had passed the IA columns: a procedure that
resulted in decrease of IgG plasma levels by approximately
40% during each session. After the final IA session, the
patients received 0.5 g/kg polyclonal IgG (Venimmun N)
over a period of 6 h, in order to restore the IgG plasma
levels. Immunoadsorption courses 2 through 4 were per-
formed until month 3, at one-month intervals and with one
session daily on two consecutive days (Fig. 1). After the final
session of each course, 0.5 g/kg of polyclonal IgG was again
substituted intravenously. The second and third courses
(courses II and III) were performed without hemodynamic
monitoring. During the fourth course (course IV), hemo-
dynamic monitoring with a Swan-Ganz thermodilution
catheter again took place four times a day: one day before IA
and proceeding until one day after IA. Left ventricular
ejection fraction was determined by two-dimensional echo-
cardiography, performed at baseline and after three months.
In addition to echocardiography, hemodynamic measure-
ments were carried out among control patients after three
months, at baseline throughout one day.
For all patients, relief of symptoms and results of clinical
examination were documented by independent attending
physicians unaware of whether the patients belonged to the
control group or to the IA/IgG group.
Histological examination. As an initial step, five right
ventricular biopsies were obtained from all patients from the
interventricular septum. Biopsies were fixed in 4% formalin
and embedded in paraffin. The sections were 2 mm thick. In
all cases, we excluded acute myocarditis according to the
Dallas criteria. Immunohistochemical staining took place in
addition to conventional histology. The immunohistochem-
ical staining procedure with the labeled streptavidin-biotin
method was used for identification of inflammatory cells.
The cells were counted as described elsewhere (18). The
following antibodies were used: anti CD3; anti CD4; anti
CD8. The antibodies were obtained from DAKO (Ham-
burg, Germany) and Novacastra (Newcastle upon Tyne,
United Kingdom).
Blood rheology. We tested blood samples within 3 h after
venous puncture. A plasma-viscometer (Fresenius, Bremen,
Germany) was used for measurement of plasma viscosity.
Whole-blood viscosity was determined with a Ubbelhode
Microviscometer (DIN 51 562, Schott, Germany) at a wall
shear rate of 800 s21, corresponding to shear rates in arteries
and capillaries. The measurements with this capillary vis-
Figure 1. Time schedule of immunoadsorption (IA) and cardio-
vascular monitoring; IA was performed in four courses until the
third month.
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cometer took place in a water bath at 25 6 0.2°C, with
precision of 62%. A Sysmex K 100 Cell Counter (TOA
Medical Electronics Co., Kobe, Japan) was used for deter-
mination of hematocrit.
Immunological parameters. Serum supernatants were
harvested from native venous blood samples and were stored
at 270°C until analysis of soluble immune mediators by
commercially available enzyme immunoassays. Tumor ne-
crosis factor alpha (TNFalpha), interleukin (IL)-6 and
soluble IL-2 receptor (sIL-2R, CD25) concentrations were
determined using the automated Immulite chemilumines-
cence enzyme immunoassay system (DPC Biermann, Bad
Nauheim, Germany). Serum levels of soluble tumor necrosis
factor receptor I (sTNF-R1) and II (sTNF-R2) were
analyzed by the respective Quantikine ELISA kits (DPC
Biermann). Determination of beta-receptor autoantibodies
took place under the direction of Gerd Wallukat, as previ-
ously described (19). Assessment of all laboratory data took
place in a blinded fashion without knowledge of the
patients’ treatment.
Statistics. Results are expressed as mean 6 SEM. Changes
in interesting clinical outcomes over time were analyzed
using nonparametric repeated measures analysis of variance
with data alignment. The analyses performed involved
comparisons between the treatment groups (with IA vs.
without IA), as well as within the groups. After overall
testing within the groups, post-hoc analyses (Wilcoxon
tests) took place in order to detect specific differences
between certain periods of treatment. In addition, differ-
ences between the two treatment groups with respect to
certain interesting times were investigated by means of the
Mann-Whitney U test. Adjustments for multiple compar-
isons were carried out using a sequentially rejective test
procedure (Bonferroni-Holm) for the periods of follow-up
after course I, before course IV and after course IV, which
are of primary clinical interest. Changes in NYHA classifi-
cation after treatment were analyzed by singly ordered 2 3
4 contingency tables (two treatments, four classes) using the
Kruskal-Wallis test of identically distributed rows (treat-
ments). Significance was assessed at the p , 0.05 level.
RESULTS
Characteristics of patients. Table 1 lists the clinical char-
acteristics, the hemodynamic data and the immunohisto-
chemical findings at baseline. In the control group and the
IA/IgG group, the following were comparable: age, disease
duration, NYHA classification, immunohistochemical find-
ings and hemodynamic parameters at baseline. Left ventric-
ular ejection fraction and left ventricular end-diastolic di-
ameter (LVEDD) were also similar in both groups.
Hemodynamic and clinical findings. In the control group,
no change was determined for the following during
follow-up tests: LVEF, CI, stroke volume index (SVI),
heart rate (HR), mean arterial blood pressure (BPmean),
mean pulmonary arterial pressure (PAPmean), PCWP,
right atrial pressure (RAP), SVR and pulmonary vascular
resistance (PVR). After three months, upon final hemody-
namic monitoring, none of the measured hemodynamic and
echocardiographic parameters differed from those at base-
line when the study was started (Fig. 2, A to D).
All patients tolerated IA and subsequent IgG substitution
well. No major complications such as infection, major
bleeding or worsening of renal function occurred. During
the first IA course, IgG and beta-receptor autoantibody
levels (Fig. 3) decreased in the IA/IgG group from 10.9 6
0.8 to 2.2 6 0.3 g/L (p , 0.01) and from 4.83 6 0.21 to
0.38 6 0.06 relative U, respectively. Simultaneously, CI
significantly increased in the IA/IgG group from 2.1 6 0.1
to 2.8 6 0.1 liter/min/m2 (p , 0.01) (Fig. 2A). Since heart
rate remained stable, SVI also significantly increased: from
27.8 6 2.3 to 36.2 6 2.5 ml/m2 (p , 0.01) (Fig. 2B).
Systemic vascular resistance decreased from 1,428 6 74 to
997 6 55 dyne z s z cm25 (p , 0.01) (Fig. 2C), and PVR fell
from 200 6 16 to 135 6 11 dynezszcm25 (p , 0.01). Mean
arterial blood pressure, PAP mean, PCWP and RAP did
not change significantly in the IA/IgG group. Hemody-
namic improvement already occurred after the first IA
session—before IgG substitution (Fig. 2, A to C).
During follow-up as well, hemodynamic improvement
Table 1. Clinical, Immunohistochemical and Hemodynamic




Age (yrs) 55.3 6 2.4 49.7 6 3.2
Disease duration (yrs) 4.3 6 0.7 4.1 6 0.5




CD3 3.6 6 1.0 3.1 6 0.8
CD4 1.4 6 0.2 1.2 6 0.3
CD8 1.9 6 0.6 1.8 6 0.4
Hemodynamics
HR (/min) 84.5 6 3.1 79.5 6 4.5
CI (liter/min/m2) 2.3 6 0.1 2.1 6 0.1
SVI (ml/m2) 27.6 6 1.3 27.8 6 2.3
PCWP (mm Hg) 17.6 6 2.7 16.0 6 2.7
RAP (mm Hg) 6.4 6 1.6 6.0 6 1.7
BPmean (mm Hg) 83.2 6 1.6 84.7 6 2.0
PAPmean (mm Hg) 26.5 6 3.1 27.1 6 2.6
SVR (dynezszcm25) 1,400 6 38 1,428 6 74
PVR (dynezszcm25) 160 6 13 200 6 16
Echocardiography
LVEDD (mm) 69.0 6 2.1 69.0 6 2.5
LVEF (%) 20.1 6 1.2 22.6 6 1.7
BPmean 5 mean arterial blood pressure; CD 5 cluster of differentiation; CI 5
cardiac index; HR 5 heart rate; LVEDD 5 left ventricular end-diastolic diameter;
LVEF 5 left ventricular ejection fraction; PAPmean 5 mean pulmonary arterial
pressure; PCWP 5 pulmonary capillary wedge pressure; PVR 5 pulmonary vascular
resistance; RAP 5 right atrial pressure; SVI 5 stroke volume index; SVR 5 systemic
vascular resistance.
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persisted in the IA/IgG group. At month 3, before the last
IA course, CI 2.8 6 0.2 liter/min/m2 (p , 0.05 vs.
baseline), SVI 36.7 6 4.4 ml/m2 (p , 0.05 vs. baseline) and
SVR 1,050 6 52 dynezszcm25 (p , 0.01 vs. baseline) were
at levels comparable with those measured after the first
course of IA. The fourth IA course subsequently induced
moderate further increase of CI and SVI to 3.0 6 0.3
liter/min/m2 (p , 0.01 vs. baseline, p , 0.05 vs. controls,
p 5 0.054 vs. results before last course) and to 42.2 6 5.4
ml/m2 (p , 0.01 vs. baseline, p , 0.05 vs. controls, p ,
0.05 vs. results before last course) (Fig. 2, A and B).
Changes in these hemodynamic outcomes over the entire
study period were analyzed using nonparametric repeated
measures analysis of variance with data alignment. This
analysis yielded significant differences for the analyzed
parameters between the groups (p , 0.05), as well as within
the IA/IgG group (p , 0.01). No significant changes were
found in the control group. For the periods of interest,
multiple comparisons (Bonferroni-Holm) of the hemody-
namic parameters were significant within the IA/IgG group
(Wilcoxon test). Comparisons between the two groups (U
tests) provided results with multiple significance.
After three months, improvement in hemodynamic find-
ings was paralleled by a comparable increase in LVEF (p ,
0.01) (Fig. 2D). Before the fourth IA course, anti-beta-
receptor autoantibodies had again increased; they decreased
subsequently during the last IA course (Fig. 3).
The patients’ functional state paralleled their hemody-
Figure 2. Changes in hemodynamics in the immunoadsorption/immunoglobulin group (IA/IgG group, filled bars, n 5 9) and in the
control group (controls, open bars, n 5 9). (A) Cardiac index. (B) Stroke volume index. (C) Systemic vascular resistance. (D) Changes
in left ventricular ejection fraction, as assessed by echocardiography. *p , 0.05; **p , 0.01 significantly different from baseline; 1p , 0.05;
11p , 0.01 significantly different from controls.
Figure 3. Changes in beta-receptor antibody level in the immu-
noadsorption/immunoglobulin group (IA/IgG group, filled bars,
n 5 9) and in the control group (controls, open bars, n 5 9). *p ,
0.05; **p , 0.01 significantly different from baseline; 1p , 0.05;
11p , 0.01 significantly different from controls.
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namic response. Examination after three months disclosed
that symptoms improved in the IA/IgG group, as indicated
by improvement in NYHA heart-failure classification (p ,
0.05 vs. baseline, Table 2). In contrast, the patients in the
control group obtained no relief from symptoms.
The doses of ACE inhibitors, nitrates, digitalis and
beta-blockers were modified neither in the control group
nor in the IA group throughout the entire study period. If
necessary, dosage of the diuretics was changed on discretion
of the attending physicians. However, the mean dosage of
the diuretics did not change significantly for either group
throughout the entire study period.
The Ethics Committee of the Charite´ Hospital termi-
nated the study after 18 patients had undergone the final
hemodynamic evaluation and after significant improvement
in hemodynamics was documented for the IA/IgG group.
Assessment of laboratory data. The combination of IA
and IgG treatment had no significant influence on plasma
and whole-blood viscosity, fibrinogen or hematocrit (Table
3). Plasma levels of TNFalpha, sTNF-R1 and -R2, IL-6
and sIL-2R were comparable in the control group and in the
IA/IgG group at baseline (Table 3). No significant changes
in proinflammatory cytokines or in soluble receptors became
apparent during further follow-up tests until month 3 in the
control group or in the IA/IgG group. For neither of the
groups, furthermore, were laboratory signs of inflammation
observed. Erythrocyte sedimentation rate and C-reactive pro-
tein remained stable. Immunoadsorption and immunoglobulin
G substitution likewise produced no significant influence on
the differential blood count. Clinical examination, in addi-
tion, did not disclose signs of infections in the study patients
during follow-up. Serum levels of cholesterol and LDL
cholesterol were not modulated by IA in combination with
IgG substitution. Immunoadsorption and immunoglobulin G
substitution also did not affect the activity of serum gluta-
mate oxalacetate transaminase or of glutamate pyruvate
transaminase. Immunoadsorption and immunoglobulin G
substitution did not modulate renal function. In the control
group and in the IA/IgG group, serum creatinine and
creatinine clearance remained unchanged in both groups.
DISCUSSION
Abnormalities of the humoral immune system in DCM.
An association between myocarditis and DCM has been
hypothesized for a subset of patients with DCM (18,20).
Abnormalities of the cellular and humoral immune system
are present in patients with myocarditis and DCM (2,3). A
number of different cardiac autoantibodies against cardiac
cellular proteins have been identified in patients with
myocarditis and DCM. Among patients with DCM, vari-
ous cardiac cellular proteins have been identified as antigens:
e.g., cardiac myosin, the beta1-receptor, the Ca
21 ATPase,
the Ca21 channel, the muscarinergic M2 receptor and the
adenine nucleotide translocator (4–8). It is unclear, how-
ever, whether these antibodies are directly pathogenic (21)
or whether they merely represent humoral markers of
autoimmunity in myocarditis and DCM. In vitro data
indicate for certain antibodies a negative effect on cardiac
performance (4,8). If cardiac autoantibodies, in fact, play a
role as causal agents in initiating or triggering the disease
Table 2. New York Heart Association Classification of the
Control Group and of the IA/IgG Group at Baseline and After










I — — — 2
II — 1 — 2
III 8 5 6 5
IV 1 3 3 —
IA/IgG 5 immunoadsorption/immunoglobulin G serum; NYHA 5 New York
Heart Association.
Table 3. Course of Selected Parameters of Blood Rheology and of Cytokine Metabolism at Baseline and After Three Months in the
Control Group and in the Immunoadsorption/Immunoglobulin G (IA/IgG) Group
Baseline After Three Months
Controls IA/IgG Group Controls IA/IgG Group
Blood viscosity (mPazs) 4.01 6 0.1 3.94 6 0.2 4.04 6 0.02 3.84 6 0.14
Plasma viscosity (mPazs) 1.19 6 0.03 1.55 6 0.24 1.31 6 0.09 1.27 6 0.13
Hematocrit 0.42 6 0.01 0.42 6 0.01 0.42 6 0.01 0.4 6 0.01
Hematocrit/blood
viscosity (/mPazs)
0.11 6 0.004 0.11 6 0.004 0.11 6 0.002 0.10 6 0.003
Fibrinogen (mg/dl) 3.27 6 0.23 3.0 6 0.24 3.68 6 0.26 3.09 6 0.13
TNFalpha (pg/ml) 13.9 6 2.6 14.0 6 1.4 14.6 6 2.7 18.2 6 3.8
IL-6 (pg/ml) 19.2 6 3.0 23.2 6 3.4 10.8 6 1.7 22.4 6 6.7
sIL-2R (U/ml) 679 6 117 928 6 252 698 6 154 1,175 6 548
sTNF-RI (pg/ml) 1,169 6 74 1,144 6 80 987 6 92 1,228 6 144
sTNF-RII (pg/ml) 2,974 6 293 2,924 6 331 2,330 6 234 3,505 6 401
IL 5 interleukin; sIL-2R 5 soluble IL-2 receptor; sTNF-R 5 soluble tumor necrosis factor receptor; TNFalpha 5 tumor necrosis factor alpha.
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process, their elimination or blockade would be expected to
improve myocardial function.
Therapeutic effects of IA and IgG substitution. The data
obtained in this study clearly indicate that IA and subse-
quent IgG substitution may represent an additional thera-
peutic tool for stabilization of the cardiovascular function of
patients with severe heart failure due to DCM. This therapy
induced short-term hemodynamic improvement as shown
by pronounced increase in CI and SVI (Fig. 2, A and B).
Furthermore, the beneficial hemodynamic effects have
proved to be of prolonged duration. Symptomatic relief
paralleled the patients’ hemodynamic response.
Possible mechanisms of hemodynamic improvement.
The underlying mechanisms of the beneficial effects of IA
and IgG substitution remain to be elucidated. At least
theoretically, physical inactivity during the procedure may
have additionally contributed to the observed stabilization
of cardiovascular function. Bed rest, however, did not
contribute to hemodynamic improvement in the IA/IgG
group. This conclusion is based on the following: during the
first course, the randomly assigned control patients were
subjected to bed rest over a period of five consecutive days,
without observed changes in hemodynamic parameters. The
beneficial effects of IA in combination with IgG substitu-
tion are related neither to reduction of left ventricular
preload caused by loss of plasma volume nor to increased
urine production due to primary improvement of renal
function. Throughout a period of three months, PCWP and
hematocrit remained stable, and creatinine clearance in the
IA/IgG group did not change significantly. Immunoadsorp-
tion and IgG substitution may also have modulated plasma
and whole-blood viscosity. Compared with the control
group, however, the IA/IgG group demonstrated no signif-
icant changes in plasma, whole-blood viscosity or hemato-
crit (Table 3).
Infections or line sepsis may have induced a decrease in
vascular resistance and a concomitant increase of CI. How-
ever, neither clinical examination nor laboratory data re-
vealed any signs of infection in the study patients during the
study period. At least theoretically a decrease of serum levels
of cholesterol may have contributed to the observed im-
provement of vascular resistance. However, IA did not
influence serum levels of LDL cholesterol. We cannot,
however, definitively exclude the possibility that peripheral
vascular events are responsible for the cardiac effects of IA
and IgG substitution. It remains unclear whether the
hemodynamic response to IA is characterized by direct
improvement of myocardial contractile function— or
whether it is due to vasodilation and a decrease in systemic
vascular resistance.
Finally, IA and IgG substitution may have nonspecifically
affected the immune system: in particular, cytokine metab-
olism. Cytokines are recognized as essential markers of
immune responses in heart failure of various etiologies,
including DCM. In patients with congestive heart failure,
increased levels of circulating cytokines have been earlier
described (22–25). Tumor necrosis factor alpha has been
reported to depress myocardial contractility (26). It is,
therefore, conceivable that the beneficial effects of IA are
caused, at least in part, by a decrease in cytokine serum
levels. During IA, however, there was no significant alter-
ation in the serum levels of the measured proinflammatory
cytokines TNFalpha and IL-6, of the soluble TNF recep-
tors I and II or of the IL-2 receptors. This result concurs
with a previous report on the relevance of TNFalpha and
TNFalpha 1 and 2 receptors in decompensated heart failure
and the effects of clinical interventions on short-term
elaboration of this cytokine (27). Despite clinical improve-
ment, the cited report noted no alteration of the high levels
of TNFalpha.
Immunohistochemical examination of the endomyocar-
dial biopsies was comparable in the IA/IgG and control
groups. The present data do not allow conclusions on
whether the efficacy of IA and IgG substitution depend on
a persistent latent inflammatory process in the myocardial
tissue. Large-scale studies are necessary to clarify this
question.
Functional role of cardiac autoantibodies. The functional
role of a particular cardiac autoantibody is still speculative.
This study provides no data that allow conclusions on
whether the acute hemodynamic effects of IA were related
to removal of a specific cardiac autoantibody. Since the IA
columns used in this study were oriented to human IgG in
general, no conclusion is possible on whether the observed
beneficial effects were due to extraction of a specific anti-
body from the sera. In particular, the contribution of the
beta-receptor autoantibodies to cardiac malfunction in
DCM is unclear. We, therefore, used these antibodies as an
immunological marker of DCM and, in turn, as a means of
evaluating the efficacy of IA in removing IgG-type antibod-
ies. It was recently shown in patients with DCM who were
treated with mechanical cardiac support systems that beta1-
receptor autoantibodies gradually decreased (28). This im-
plies that this type of cardiac autoantibody may be a marker
of functional recovery. It remains to be elucidated whether
cardiac autoantibodies represent an epiphenomenon in
DCM, whether they play a causal role in initiating cardiac
injury or whether they contribute to cardiac malfunction
after the disease has developed. In any case, a recent report
by Matsui et al. (29) is of particular interest. These authors
provided evidence that peptides derived from cardiovascular
G-protein-coupled receptors induce morphological cardio-
myopathic changes in the myocardium of immunized rab-
bits, which are similar to those found in humans with
DCM.
Possible effects of IgG substitution. Hemodynamic mea-
surements carried out during the first IA course revealed
significant hemodynamic improvement, which had already
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taken place before IgG substitution. On the other hand, in
addition to IA, substitution of IgG also modulates the
immune system. Beneficial effects of intravenous Ig therapy
have been reported for various autoimmune diseases
(11,13,15). Also in DCM, administration of intravenous
IgG may improve the disease process. According to a recent
report on patients with myocarditis and acute cardiomyop-
athy, the use of high-dose intravenous IgG was associated
with significant increase in left ventricular performance at
one-year follow-up (17). Administration of intravenous Ig
after IA may, therefore, be a confounding variable. How-
ever, we considered IgG substitution necessary—after IA
and subsequent IgG depletion—in order to reduce the risk
of infection in our patients instrumented with a pulmonary
catheter. According to clinical data, risk of acute infection
increases when IgG plasma levels fall below 5g/dl (30).
Another reason for IgG substitution was to prevent rebound
of antibody production in the B cells. Anti-idiotypic IgG
inhibits autoantibody production in B cells by binding of the
Ig to B-cell Fc-receptors (10). Furthermore, substitution
with intravenous IgG causes idiotype-anti-idiotype reac-
tions and neutralization of the remaining autoantibodies.
In summary, IA—in combination with IgG substitution
and with repetition at monthly intervals—induces stable
hemodynamic improvement and may, therefore, represent
an additional beneficial therapeutic approach in patients
with DCM.
Study limitations. The design of this study was not ade-
quately controlled and blinded, owing to the fact that the
control group was not sham treated by plasmapheresis and
subsequent reinfusion of the plasma without IA. This
treatment procedure, however, was considered inappropri-
ate on ethical grounds.
Conclusions. These data indicate that activation of the
humoral immune system, with production of cardiac auto-
antibodies, may play a functional role in cardiac malfunction
of patients with DCM. Modulation of the humoral immune
system by IA and subsequent IgG substitution may, accord-
ingly, represent a promising therapeutic approach which
intervenes in this autoimmune process.
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